Antengene (FRA:722) ROA %: -25.86% (As of Dec. 2025)


FRA:722 Antengene Corp Ltd FRA:722
40 GF Score
Price €0.35
GF Value €0.16
! 5 Warning Signs
View Full Analysis

What is Antengene ROA %?

Antengene FRA:722 -3.33% 40 ROA % is -25.86% as of Dec. 2025. GuruFocus rates FRA:722 with a GF Score™ of 40/100 and a GF Value™ of €0.16. The stock has 5 warning signs investors should review. Among 1,422 Biotechnology companies, Antengene ranks better than 61.46% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Antengene's annualized Net Income for the quarter that ended in Dec. 2025 was €-39.47 Mil. Antengene's average Total Assets over the quarter that ended in Dec. 2025 was €152.62 Mil. Therefore, Antengene's annualized ROA % for the quarter that ended in Dec. 2025 was -25.86%.

The historical rank and industry rank for Antengene's ROA % or its related term are showing as below:

FRA:722' s ROA % Range Over the Past 10 Years
Min: -181.5   Med: -27.43   Max: -18.71
Current: -18.77

During the past 8 years, Antengene's highest ROA % was -18.71%. The lowest was -181.50%. And the median was -27.43%.

FRA:722's ROA % is ranked better than
61.46% of 1422 companies
in the Biotechnology industry
Industry Median: -32.87 vs FRA:722: -18.77

Antengene  (FRA:722) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-39.468/152.6175
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-39.468 / 12.648)*(12.648 / 152.6175)
=Net Margin %*Asset Turnover
=-312.05 %*0.0829
=-25.86 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Antengene ROA % Related Terms


Antengene ROA % Historical Data

* Premium members only.

The historical data trend for Antengene's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antengene ROA % Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
Get a 7-Day Free Trial -24.07 -25.24 -29.98 -21.80 -17.64

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.07 -21.66 -21.97 -11.21 -25.86

FRA:722 vs VRTX, REGN, ALNY: ROA % Comparison

For the Biotechnology subindustry, Antengene's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antengene ROA % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's ROA % distribution charts can be found below:

* The bar in red indicates where Antengene's ROA % falls into.


FRA:722
40GF Score
Antengene Corp Ltd FRA:722
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antengene ROA % Calculation

Antengene's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-28.995/( (176.387+152.417)/ 2 )
=-28.995/164.402
=-17.64 %

Antengene's annualized ROA % for the quarter that ended in Dec. 2025 is calculated as:

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-39.468/( (152.818+152.417)/ 2 )
=-39.468/152.6175
=-25.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -25.86% mean?
Antengene (FRA:722) has a ROA % of -25.86% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Antengene and its competitors. According to the industry distribution chart, Antengene ranks #548 out of 1422 companies in the Biotechnology industry, placing it in the top 38.5%.
Is Antengene's ROA % too high?
Antengene's current ROA % is -25.86%. Based on the distribution chart, Antengene ranks #548 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Antengene has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Antengene's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Antengene ranks #548 out of 1422 companies for ROA %. This puts Antengene in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Antengene and its competitors. Antengene's current ROA % is -25.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antengene stock overvalued right now?
Antengene (FRA:722) has a current ROA % of -25.86%. The stock's GF Value™ is €0.16, compared to a current price of €0.35 — trading 117.5% above its estimated fair value. The current ROA % is -25.86%. Antengene's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Antengene (FRA:722), the current ROA % is -25.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antengene (FRA:722) Overvalued in 2026?

Based on GuruFocus' analysis, Antengene stock appears to be overvalued. The current stock price of €0.35 is trading 117.5% above its estimated GF Value™ of €0.16.

Key valuation signals for FRA:722:

  • ROA %: -25.86%
  • GF Value™: €0.16 vs. price of €0.35 (117.5% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the FRA:722 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Antengene Business Description

Other Exchanges 06996:Hong Kong
Address 1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
40GF Score

Get the complete analysis for FRA:722

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.35
Price
€0.16
GF Value